Mumbai, Nov 30: Pharma Major, Cipla Ltd, today announced that it has received an approval for
its product Q-TIB from World Health Organisation (WHO).
Q-TIB is a novel fixed dose combination in a single tablet. This is the first time that such a combination has been made available in the world. Cipla will market the product globally.
Q-TIB will help prevent tuberculosis infection in people living with HIV. People living with HIV face a challenged immune system and are prone to opportunistic infections, which constitute the major source of premature deaths among them.
As per Global TB Report, 2016, by WHO, about one million people died of AIDS-related illness. Most of them succumbed to opportunistic infections, and among them, 400,000 died of tuberculosis. UNI
Q-TIB is a novel fixed dose combination in a single tablet. This is the first time that such a combination has been made available in the world. Cipla will market the product globally.
Q-TIB will help prevent tuberculosis infection in people living with HIV. People living with HIV face a challenged immune system and are prone to opportunistic infections, which constitute the major source of premature deaths among them.
As per Global TB Report, 2016, by WHO, about one million people died of AIDS-related illness. Most of them succumbed to opportunistic infections, and among them, 400,000 died of tuberculosis. UNI
Post A Comment:
0 comments so far,add yours